$1.58
−5.39%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.66
From 52W high−87.02%
Volume781719.00
Market cap$105.89M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.66
From 52W high
−87.02%
Volume
781719.00
Market cap
$105.89M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.0x
P/E (TTM)
—
RSI (14)
38.8
MomentumView details →
1D Return
−5.39%
YTD Return
−81.83%
SummaryUpdated Jul 1, 2026
enGene Holdings Inc. (NASDAQ:ENGN) is a clinical-stage biotechnology company founded in 2023 and based in Saint-Laurent, Canada. The company went public in February 2022 and operates through its subsidiary enGene, Inc. enGene focuses on developing genetic medicines delivered to mucosal tissues and other organs, representing a specialized approach within the broader gene therapy field. As a clinical-stage company, enGene has not yet generated revenue and is currently advancing its lead therapeutic candidate through clinical trials.
Similar companies
Latest newsMore news →
enGene Therapeutics Inc. reported its Q3 2026 financial results, with a net loss of $32.5 million and diluted EPS of -$0.47, and cash and marketable securities of $266.3 million.42d agoRichard Glickman resigned as director and chairman of the Board of Directors of enGene Therapeutics Inc., effective July 15, 2026.96d ago